AZD7687
AZD7687 is a potent, selective, reversible and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor with an IC50 of 80 nM for human DGAT1. AZD7687 can be used for type 2 diabetes mellitus and obesity research[1][2].
Product Specifications
CAS Number
1166827-44-6
UNSPSC
12352005
Hazard Statement
H302
Target
Acyltransferase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/azd7687.html
Purity
99.80
Solubility
DMSO : ≥ 50 mg/mL
Smiles
CC1=C(C(N)=O)N=C(C2=CC=C([C@H]3CC[C@H](CC(O)=O)CC3)C=C2)C(C)=N1
Molecular Formula
C21H25N3O3
Molecular Weight
367.44
Precautions
P264-P270-P330-P501
References & Citations
[1]Barlind JG, et al. Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687) . J Med Chem. 2012 Dec 13;55 (23) :10610-29.|[2]Denison H, et al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2013 Oct 4.|[3]Eike Floettmann, et al. Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse. Toxicol Pathol. 2015 Apr;43 (3) :376-83.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Phospho-MLKL (S345) Recombinant Rabbit Monoclonal Antibody [JM92-37]](https://cdn.genprice.uk/products/992/68dd1c90061270361ea8299e/imageurl/et1705-51.webp)
ET1705-51 100 µL
Phospho-MLKL (S345) Recombinant Rabbit Monoclonal Antibody [JM92-37]
Sign In for Pricing
View Details 
